Skip to content

Search for:
Home
About HubLE
Content
IFMRS
MSK-KP
Other
Menu

Albert Kim

Garvan Institute of Medical Research, Australia

Sequential zoledronate therapy prevent rebound bone loss following withdrawal of RANKL inhibition

7 December 2021

Categories HubLE Exchange Tags ANZBMS, ANZBMS 2021, bone density, Osteoclasts, Osteoporosis, Translational

Search for:

Recent Posts

Addressing musculoskeletal conditions: an opportunity for health systems globally
Autoantibody mediated inflammation co-activates FcgR and IFNgR pathways in osteoclasts
Protein O-GlcNAcylation modulates osteoclast formation
The cherubism bone phenotype is independent of the inflammasome activation
Gut Microbiome and Bone health: Unveiling the Unexpected in Germ-Free C57BL/6 Mice

Recent Comments

Diego Grinman on Site-specific alterations in murine osteocyte lacuno-canalicular network inflicted with osteotropic tumor cells
Diego on HubLE Advice by Professor Ego Seeman
Allison Pettit on For increase recognition for the importance of laboratory-based discovery research

Archives

Categories

Archive: HubLE Graphics
HubLE Exchange
HubLE Graphics
HubLE Opinions
HubLE Publications
HubLE Resources
Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

CONTACT US
PRIVACY POLICY
DISCLAIMER

Menu

CONTACT US
PRIVACY POLICY
DISCLAIMER

© 2021-2023 – International Federation of Musculoskeletal Research Societies

Home
About HubLE
Content
IFMRS
MSK-KP
Other